IL6 and COVID-19: It is the condition for discussing the possible interest of evaluating type 1 IFN treatment in patients with severe COVID-19 who harbor type 1 IFN decline before the critical phase of the disease, eventually combined with anti-inflammatory drugs like dexamethasone and IL-6 inhibitors.